Clopidogrel Tablet, Film Coated
Product Images NDC 69367-200

Product Visual Gallery

This gallery contains 11 technical images submitted to the FDA as part of the official labeling for Clopidogrel (NDC 69367-200). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Westminster Pharmaceuticals, Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Chemical Structure (Clopidogrel 01)

Chemical structure of clopidogrel bisulfate, showing the molecular arrangement with a thiophene ring, piperidine ring, chlorophenyl group, and sulfate ion (H2SO4) as part of the salt form.*

FDA Label Image

Figure 1 (Clopidogrel 02)

A horizontal error bar chart comparing four medications: Dexlansoprazole 60 mg, Lansoprazole 30 mg, Pantoprazole 80 mg, and Omeprazole 80 mg. The x-axis ranges from 0.4 to 1.4, and each medication name is listed on the left side aligned with its corresponding data points and error bars, illustrating comparative values with associated variability.*

FDA Label Image

Figure 2 (Clopidogrel 03)

A cumulative event rate line graph comparing cardiovascular death, myocardial infarction, and stroke over 12 months of follow-up between Clopidogrel (+ aspirin) and placebo (+ aspirin) treatment groups. The graph shows event rates plotted over time with statistically significant differences noted (P=0.00009). Additional standard therapies were used as appropriate.*

FDA Label Image

Figure 3 (Clopidogrel 04)

A forest plot showing hazard ratios with 95% confidence intervals for Clopidogrel compared to placebo across various subgroups including age, gender, race, elevated cardiac enzymes, diabetes, previous myocardial infarction, and previous stroke. The graph visually compares the effectiveness of Clopidogrel versus placebo with subgroup sample sizes and event counts.*

FDA Label Image

Figure 4 (Clopidogrel 05)

A forest plot showing hazard ratios with 95% confidence intervals comparing Clopidogrel versus placebo across subgroups including Heparin/LMWH use, Aspirin dosage (<100 mg, 100-200 mg, >200 mg), GPIIb/IIIa antagonist usage, Beta-Blocker use, and ACE inhibitor use, and overall. The x-axis represents hazard ratio from 0.3 to 1.4, indicating whether outcomes favor Clopidogrel or placebo based on subgroup analyses from a clinical study.*

FDA Label Image

Figure 5 (Clopidogrel 06)

A Kaplan-Meier survival curve showing percentage dead before first discharge over 28 days since randomization, comparing Clopidogrel treatment versus placebo. The graph illustrates deaths and risk reduction percentages for both groups, highlighting a 7% proportional risk reduction with Clopidogrel.*

FDA Label Image

Figure 6 (Clopidogrel 07)

A Kaplan-Meier curve chart showing the percentage of patients with death, reinfarction, or stroke before first discharge over 28 days since randomization. It compares two groups: Placebo (10.1% event rate, 2310 patients) and Clopidogrel (9.2% event rate, 2121 patients), with a noted 9% proportional risk reduction (p=0.002). The vertical axis is labeled '% with death, re-infarction or stroke before first discharge' and the horizontal axis is 'Days since randomization (up to 28 days)'.*

FDA Label Image

Figure 7 (Clopidogrel 08)

A forest plot presenting odds ratios with 99% confidence intervals for different subgroups comparing Clopidogrel and Placebo. Subgroups include gender, age at entry, hours since onset, systolic blood pressure (SBP), heart rate, and fibrinolytic agent given. The plot visually shows which treatment is favored across these subgroups based on the odds ratio scale from 0.6 to 1.3.*

FDA Label Image

Figure 8 (Clopidogrel 09)

A line chart comparing cumulative event rates (%) of fatal or non-fatal vascular events over 36 months of follow-up between Aspirin and Clopidogrel treatments. The graph shows event rates increasing over time, with Clopidogrel having a slightly lower event rate than Aspirin. A p-value of 0.045 is indicated on the chart.*

FDA Label Image

Principal Display Panel (300 mg Tablet Bottle Label)

A forest plot chart showing hazard ratios with 95% confidence intervals comparing Clopidogrel versus Aspirin across different qualifying conditions: Stroke, MI, PAD, and Overall. The chart includes numeric data for sample size (N) and event counts for Clopidogrel and Aspirin groups, depicting relative favorability on a horizontal axis ranging roughly from 0.6 to 1.3.*

FDA Label Image

Clopidogrel 11

Clopidogrel 300 mg film-coated tablets label from Westminster Pharmaceuticals, LLC. The label indicates 30 tablets, emphasizes the prescription-only status, and includes manufacturer SciGen Pharmaceuticals, Inc. It provides dosage and storage information, barcode, and the phrase 'NO VARNISH' on the side.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.